Monarch Partners Asset Management LLC Crinetics Pharmaceuticals, Inc. Transaction History
Monarch Partners Asset Management LLC
- $328 Million
- Q4 2022
A detailed history of Monarch Partners Asset Management LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Monarch Partners Asset Management LLC holds 128,974 shares of CRNX stock, worth $5.46 Million. This represents 0.72% of its overall portfolio holdings.
Number of Shares
128,974
Previous 130,860
1.44%
Holding current value
$5.46 Million
Previous $2.57 Million
8.17%
% of portfolio
0.72%
Previous 0.77%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
237Shares Held
90.2MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$392 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$271 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$264 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$246 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$237 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.27B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...